Evidence map›Paper›PMID 39902939›Full record

ArticleMicrobiology spectrum2025

Exploring the effect of sequential antibiotic exposure in resistant

Lisa Göpel, Laura Kirchhoff, Olivia Gopleac, Leif Tüeffers, Susanne Hauswaldt, Sébastien Boutin, Jan Rupp, Dennis Nurjadi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Microbiology spectrum, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Lisa GöpelUniversity of Lübeck and University Hospital Schleswig-Holstein Campus Lübeck, Institute of Medical Microbiology and Infectious Diseases Clinic, Lübeck, Germany.
Laura KirchhoffUniversity of Lübeck and University Hospital Schleswig-Holstein Campus Lübeck, Institute of Medical Microbiology and Infectious Diseases Clinic, Lübeck, Germany.
Olivia GopleacUniversity of Lübeck and University Hospital Schleswig-Holstein Campus Lübeck, Institute of Medical Microbiology and Infectious Diseases Clinic, Lübeck, Germany.
Leif TüeffersUniversity of Lübeck and University Hospital Schleswig-Holstein Campus Lübeck, Institute of Medical Microbiology and Infectious Diseases Clinic, Lübeck, Germany.
Susanne HauswaldtUniversity of Lübeck and University Hospital Schleswig-Holstein Campus Lübeck, Institute of Medical Microbiology and Infectious Diseases Clinic, Lübeck, Germany.
Sébastien BoutinUniversity of Lübeck and University Hospital Schleswig-Holstein Campus Lübeck, Institute of Medical Microbiology and Infectious Diseases Clinic, Lübeck, Germany.
Jan Rupp *University of Lübeck and University Hospital Schleswig-Holstein Campus Lübeck, Institute of Medical Microbiology and Infectious Diseases Clinic, Lübeck, Germany.ORCID 0000-0001-8722-1233
Dennis Nurjadi *University of Lübeck and University Hospital Schleswig-Holstein Campus Lübeck, Institute of Medical Microbiology and Infectious Diseases Clinic, Lübeck, Germany.ORCID 0000-0002-1278-5939

Funding

Bundesministerium für Bildung und Forschung (BMBF) TTU 08.824Deutsche Forschungsgemeinschaft (DFG) EXC 2167-390884018
6 · The paper itself

Abstract

Antimicrobial resistance development, particularly in infections such as urinary tract infections (UTIs), is a global clinical concern. The objective of this study was to determine if sequential antibiotic exposure with ciprofloxacin and mecillinam can reduce the growth of resistant clinical IMPORTANCE: As global rates of antibiotic resistance increase and the development of new antibiotics become more difficult and costly, it is important to explore alternative strategies to improve the effectiveness of existing antibiotics. Previous studies have shown that sequential exposure of

Indexed as

Anti-Bacterial AgentsEscherichia coliEscherichia coli InfectionsUrinary Tract InfectionsAmdinocillinCiprofloxacinDrug Resistance, BacterialDrug Resistance, Multiple, BacterialEscherichia coli ProteinsHumansMicrobial Sensitivity TestsProof of Concept StudyAmdinocillinAnti-Bacterial AgentsCiprofloxacinEscherichia coli Proteinsciprofloxacin resistanceE. colimecillinam resistancesequential therapyUTI

Identifiers

PMID39902939
PMCPMC11878055

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.